LifeVantage director logs equity grant and subsequent share sales

Rhea-AI Filing Summary

LifeVantage (LFVN) director Michael A. Beindorff reported insider activity on Form 4. On 11/06/2025, he received 13,531 shares under the outside director compensation program, scheduled to vest on November 6, 2026; the price shown is $7.76, equal to the weighted average closing price over the prior ten trading days. On 11/07/2025, he sold 1,000 shares at $7.33 (direct) and 35,000 shares at a weighted average $6.9215 (indirect via trust), with a portion sold to cover taxes from a restricted stock vesting. Following these transactions, holdings include 35,389 shares direct, 56,413 shares indirect via trust, 126 shares held by spouse as custodian for minor children, and 5,500 shares held by spouse.

Insights

Corporate governance analyst

Routine Form 4: grant plus limited sales, neutral impact.

The filing records an equity grant of 13,531 shares that vests on November 6, 2026, consistent with an outside director compensation program. The reported price of $7.76 reflects a weighted ten-day average tied to the grant methodology.

Subsequent sales on November 7, 2025 include 1,000 shares at $7.33 (direct) and 35,000 shares at a weighted average $6.9215 (indirect via trust). A portion of the indirect sales covered tax obligations from a restricted stock vesting, a common administrative action.

Post-transaction positions are disclosed as 35,389 shares direct and 56,413 shares indirect via trust, plus smaller family-held amounts. This is typical reporting, with investment implications depending on ongoing disclosures.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BEINDORFF MICHAEL A

(Last) (First) (Middle)

3300 TRIUMPH BLVD, SUITE 700

(Street)

LEHI UT 84043

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lifevantage Corp [ LFVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/06/2025		A		13,531(1)	A	$7.76(2)	36,389	D
Common Stock	11/07/2025		S		1,000	D	$7.33	35,389	D
Common Stock	11/07/2025		S		35,000(3)	D	$6.9215(4)	56,413	I	By Trust(5)
Common Stock								126	I	By Spouse as Custodian for Minor Children
Common Stock								5,500	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were granted to the reporting person pursuant to the issuer's outside director compensation program and will vest in a single installment on November 6, 2026, subject to the reporting person's continuous service to the issuer through such date.

2. The price reported in Column 4 is equal to the weighted average closing price of the issuer's common stock for the ten trading days ending the day before the date of the grant.

3. A portion of the shares sold in this transaction were sold by the Reporting Person to cover tax obligations in connection with the vesting of a restricted stock award.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.65 to $7.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The shares are held by the Michael A. Beindorff Trust U/A DTD 06/14/2000 of which the reporting person and his spouse are trustees.

Remarks:

	/s/ Alissa Neufeld, Power of Attorney for Michael Beindorff	11/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did LFVN director Michael A. Beindorff report on Form 4?

He reported a grant of 13,531 shares on 11/06/2025 and sales totaling 36,000 shares on 11/07/2025.

When do the granted LFVN shares vest and at what reference price?

They vest on November 6, 2026; the price shown is $7.76, the weighted average closing price over the prior ten trading days.

How many LFVN shares did the director sell and at what prices?

He sold 1,000 shares at $7.33 (direct) and 35,000 shares at a weighted average $6.9215 (indirect via trust).

Were any LFVN shares sold to cover taxes?

Yes, a portion of the 35,000 indirect shares was sold to cover tax obligations related to a restricted stock vesting.

What are the director’s LFVN holdings after the transactions?

Reported holdings: 35,389 shares direct; 56,413 via trust; 126 by spouse as custodian for minor children; 5,500 by spouse.

What is the relationship of the reporting person to LFVN?

The reporting person is a Director of LifeVantage Corporation.